Publication:
Liposomal nanoparticles as a drug delivery system for improved treatment of multiple myeloma

Simple item page
dc.contributor.departmentDepartment of Chemistry
dc.contributor.departmentKUTTAM (Koç University Research Center for Translational Medicine)
dc.contributor.kuauthorHanafy, Nemany Abdelhamid Nemany
dc.contributor.kuauthorKölemen, Safacan
dc.contributor.schoolcollegeinstituteResearch Center
dc.contributor.schoolcollegeinstituteCollege of Sciences
dc.date.accessioned2026-07-02T07:30:42Z
dc.date.issued2026
dc.description.abstractMultiple myeloma (MM) remains a challenging type of hematological cancer, characterized by the growth and accumulation of clonal plasma cells within the bone marrow. Current traditional therapies, mainly conventional chemotherapeutics, demonstrate limited therapeutic capacity due to considerable side effects and drug resistance. In this direction, liposomal nanotherapeutics have emerged as a promising new strategy in cancer therapy, holding great potential to address the chemical and biological constraints of existing anticancer treatments. This review presents a summary of the latest developments in the application of targeted liposomal nanoparticles as a drug carrier system for the management of MM. Furthermore, it explores the challenges linked to creating efficient drug delivery systems, targeting methods, and the processes involved in controlled drug release.
dc.description.fulltextNo
dc.description.harvestedfromManual
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.openaccessGreen Submitted, gold
dc.description.publisherscopeInternational
dc.description.readpublishN/A
dc.description.sponsoredbyTubitakEuEU - TÜBİTAK
dc.description.sponsorshipThis publication was created by benefiting from the 2236-B Marie Sklodowska-Curie Actions (MSCA) Cofund Scholarship Programs Contribution Fund Program (TUBITAK project ID: 123C460) and Horizon Europe MSCA Cofund Postdoctoral Program (EU project ID: 101126492). Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the European Union or TUBITAK. Neither the European Union nor the granting authority can be held responsible for them. The authors thank Ayca Saymaz for creating Fig. 2 and the graphical abstract.
dc.description.versionPublished Version
dc.identifier.WoSQuartileQ2
dc.identifier.doi10.1039/d5ra09823h
dc.identifier.eissn2046-2069
dc.identifier.embargoNo
dc.identifier.endpage14009
dc.identifier.grantno101126492
dc.identifier.grantno123C460
dc.identifier.issue16
dc.identifier.pubmed41835141
dc.identifier.scopus2-s2.0-105032752525
dc.identifier.startpage13995
dc.identifier.urihttps://doi.org/10.1039/d5ra09823h
dc.identifier.urihttps://hdl.handle.net/20.500.14288/33053
dc.identifier.volume16
dc.identifier.wos001713271300001
dc.keywordsMultiple myeloma
dc.keywordsLiposomal nanotherapeutics
dc.keywordsDrug delivery system
dc.languageeng
dc.publisherRoyal Society of Chemistry
dc.relation.affiliationKoç University
dc.relation.collectionKoç University Institutional Repository
dc.relation.ispartofRSC Advances
dc.relation.openaccessN/A
dc.rightsN/A
dc.rights.uriN/A
dc.subjectChemistry
dc.titleLiposomal nanoparticles as a drug delivery system for improved treatment of multiple myeloma
dc.typeReview
dspace.entity.typePublication
relation.isOrgUnitOfPublication035d8150-86c9-4107-af16-a6f0a4d538eb
relation.isOrgUnitOfPublication91bbe15d-017f-446b-b102-ce755523d939
relation.isOrgUnitOfPublication.latestForDiscovery035d8150-86c9-4107-af16-a6f0a4d538eb
relation.isParentOrgUnitOfPublicationd437580f-9309-4ecb-864a-4af58309d287
relation.isParentOrgUnitOfPublicationaf0395b0-7219-4165-a909-7016fa30932d
relation.isParentOrgUnitOfPublication.latestForDiscoveryd437580f-9309-4ecb-864a-4af58309d287

Files

Collections

Publications without Fulltext